Size, Share & Industry Analysis, By Device Automation (Automated Insulin Delivery Patch Pumps, Manually Programmed Electronic Patch Pumps, Mechanical Insulin Delivery Patches), By Patient Indication (Type 1 Diabetes, Insulin-Treated Type 2 Diabetes), By Purchasing Channel (Retail Pharmacy and Home Fulfillment, Hospital and Diabetes Clinics, Specialty Durable Medical Equipment Channels), By Replacement Design (Disposable Multi-Day Pods, Modular Reusable Micropumps, Daily Mechanical Patches), and Regional Forecast, 2026-2034
Explore the report section by section.
The global Wearable Insulin Patch Pump Market is modeled at USD 2.995 billion in 2025, increasing to USD 3.474 billion in 2026 and USD 11.389 billion by 2034 at a 16.0% CAGR. With no publisher monetary endpoints, the exact v13.2 source-backed revenue method uses Insulet's disclosed 2025 Omnipod sales and explicit allowances for other suppliers and forecast growth.
Wearable insulin patch pumps deliver insulin through an adhesive, body-worn device without long external tubing. Automated products such as Omnipod 5 can adjust basal delivery using data from a compatible continuous glucose monitor, while manually programmed patch pumps and mechanical mealtime patches serve different treatment needs. Medtrum offers a TouchCare Nano pump with 200- and 300-unit options, Roche markets a detachable Accu-Chek Solo micropump in selected countries, and MannKind's V-Go uses a mechanical daily basal-bolus format.
Insulet reported USD 2,674.0 million of Omnipod product revenue in calendar 2025, comprising USD 1,919.8 million in the United States and USD 754.3 million internationally. The company reported more than 600,000 estimated active users at year-end and nine new market launches during 2025. These figures provide a defensible minimum global patch-pump revenue base but do not separately audit all other manufacturers. The market model adds a 12% allowance for other marketed suppliers and assumes 16% annual growth after 2025, below Insulet's initial 2026 guidance of 21–23% Omnipod growth.
Omnipod 5 received a U.S. type 2 diabetes indication in August 2024 and expanded internationally during 2025 and 2026. In August 2026, Insulet reported a second-quarter Omnipod revenue increase of 24.6% and a launch in Spain, its twenty-sixth market for the product platform. Sensor integration and automated algorithms are expanding the eligible population, but clinical performance depends on compatible CGM readings, insulin settings and ongoing device training.
Device safety and cannula manufacturing quality are critical constraints for wearable insulin delivery. The FDA posted an Insulet correction in March 2026 and a separate May 2026 action involving certain Omnipod lots with possible insulin leakage and under-delivery. The May action affected roughly seven million pods, with twenty-four serious adverse event reports and no deaths at the time of the company announcement. The revenue boundary includes pump pods, reusable controllers and device-specific consumables, but excludes insulin drugs, separately sold CGM sensors, unrelated diabetes subscriptions and conventional tubed insulin pumps.
Source: Insulet 2025 financial results; FDA May 2026 Omnipod correction; Medtrum TouchCare Nano; Roche Accu-Chek Solo.
The defined category includes marketed wearable insulin delivery devices adhering directly to the skin, including electronic tubeless pumps and mechanical patches that deliver insulin through an integrated cannula or needle.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Device Automation | Automated Insulin Delivery Patch Pumps; Manually Programmed Electronic Patch Pumps; Mechanical Insulin Delivery Patches |
| By Patient Indication | Type 1 Diabetes; Insulin-Treated Type 2 Diabetes |
| By Purchasing Channel | Retail Pharmacy and Home Fulfillment; Hospital and Diabetes Clinics; Specialty Durable Medical Equipment Channels |
| By Replacement Design | Disposable Multi-Day Pods; Modular Reusable Micropumps; Daily Mechanical Patches |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; United Kingdom; Spain; Netherlands; Sweden; Australia; China; Japan; Brazil; Saudi Arabia; United Arab Emirates |
| Key Market Players | Insulet Corporation; Medtrum Technologies; Roche Diabetes Care; MannKind Corporation; CeQur |
In-scope revenue covers disposable insulin pods, tubeless pump hardware, handheld or app-linked controllers sold with the device, detachable micropump modules and mechanical basal-bolus or mealtime insulin patches. Insulet's Omnipod product revenue provides the measured core; its unrelated Drug Delivery business is excluded. The model adds a 12% supplier allowance for Medtrum, Roche, MannKind, CeQur and other qualified niche suppliers without presenting that allowance as audited global revenue.
The annual 16% growth assumption is a forward-looking model, not company guidance. Insulet reported 31.6% Omnipod growth in 2025 and projected 21–23% constant-currency growth in its February 2026 outlook, subsequently revising the 2026 range in August. Standalone CGM sensors from Abbott or Dexcom, insulin vials, pens, reimbursement for diabetes clinic visits, subscription-only software and conventional tubed pumps are outside the revenue boundary. Electronic automated and mechanical bolus-only patches are identified separately to avoid equating their clinical capabilities.
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Expansion into insulin-treated type 2 diabetes | High | +5.50% | High | High | High |
| International Omnipod and competing patch pump launches | High | +4.80% | High | High | Medium |
| CGM interoperability and automated dosing upgrades | Medium-High | +4.10% | High | High | High |
| Recurring disposable pod utilization | Medium | +3.10% | High | Medium | Medium |
| Others (wearability, pharmacy access, training support) | Low | +1.70% | Medium | Medium | Low |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Manufacturing corrections and device safety concerns | High | -1.40% | High | Medium | Low |
| Reimbursement and out-of-pocket cost barriers | Medium | -1.00% | High | High | Medium |
| Others (sensor compatibility, training, skin reactions) | Low | -0.80% | Medium | Medium | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 16.0% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
Omnipod and Medtrum devices attach directly to the skin without an external infusion tube, which can reduce daily handling for people transitioning from injections. Insulet reported more than 600,000 estimated active Omnipod users worldwide at the end of 2025. Medtrum's TouchCare Nano offers a 200-unit patch weighing 13.8 grams without insulin and a 300-unit option for higher capacity. Ease of wear supports adoption, but clinicians must still teach site rotation, bolus settings and troubleshooting for interrupted delivery.
The FDA-cleared Omnipod 5 indication for adults with type 2 diabetes in August 2024 added a population previously served largely by injections or other pumps. Insulet's automated system adjusts delivery using compatible glucose-sensor data, while MannKind V-Go offers preset basal insulin and manually triggered boluses for adults requiring insulin. These products serve different needs, so market growth should not assume every type 2 patient requires closed-loop automation. Insulin pump reimbursement and specialist-led training influence whether new type 2 users continue replacing pods after initiation.
Insulet launched Omnipod 5 in Italy, Denmark, Finland, Norway and Sweden in January 2025, then expanded into Australia and planned Canada, Belgium and Switzerland later that year. Its August 2026 update reported Spain as the twenty-sixth country with Omnipod sales. Reusable controllers and disposable pods create different replacement cycles; each three-day pod supports recurring revenue after initial system adoption. Local reimbursement, language support and sensor availability influence how quickly a market moves from launch to routine use.
The FDA reported a March 2026 correction affecting selected Omnipod 5 lots and a separate May action involving Omnipod 5, DASH and Eros pods. The May correction described potential insulin under-delivery from a small cannula tear and covered roughly seven million pods, of which about sixty percent were consumed or expired. Insulet reported twenty-four serious adverse events and no deaths at announcement. These actions increase the importance of lot traceability, replacement logistics and user training, even though unaffected pods continued to be sold.
Automated patch pumps require compatible glucose sensors, training and reliable access to replacement pods, while insurers may apply eligibility and prior authorization rules. Roche Accu-Chek Solo provides a detachable modular pump in selected European markets, but its features and market availability differ from Omnipod 5. Mechanical products such as CeQur Simplicity deliver mealtime boluses rather than automated basal insulin. Buyers must therefore compare total therapy costs and clinical functionality instead of treating all wearable insulin patches as equivalent.
Sources: Insulet investor disclosures; FDA device correction notices; Medtrum product specifications; Roche Diabetes Care; American Diabetes Association product guide.
Insulet reported FDA clearance for Omnipod 5 algorithm enhancements in 2025 and announced a next-generation algorithm during its August 2026 second-quarter update. The changes aim to improve time in range and time spent in automated mode. Sensor compatibility has expanded to Abbott FreeStyle Libre 3 Plus and Dexcom products in selected markets. These advances can increase retention among users who prefer fewer manual adjustments, although the CGM sensor itself is not counted in patch-pump revenue.
Omnipod 5 became available in five additional European countries in January 2025 and expanded to Australia in March of that year. Insulet launched in Spain during 2026 and introduced the system in Saudi Arabia, Kuwait, the United Arab Emirates and Qatar. Each market has its own reimbursement, regulatory and sensor compatibility conditions. Regional sales therefore depend on pharmacy distribution and clinician training after initial launch, rather than simply counting the number of countries on a product list.
Medtrum's Nano system supports continuous basal delivery and optional CGM integration, while Roche Accu-Chek Solo offers a detachable tube-free micropump with direct bolus buttons. MannKind V-Go uses a daily mechanical device with preset basal rates and two-unit bolus increments; CeQur Simplicity is a bolus-only mealtime patch worn for up to four days. These delivery differences determine which patients need an electronic pump rather than a mechanical bolus patch. Mechanical patches may lower device complexity but do not replace automated insulin delivery for patients who need closed-loop adjustment.
The March and May 2026 Omnipod corrections showed that small tubing or cannula defects can cause insulin under-delivery and potentially serious hyperglycemia. The FDA classified the broader May action as a Class I recall in July 2026. That designation requires robust lot identification and rapid customer contact to prevent further under-delivery. Insulet implemented manufacturing process changes and provided affected-lot checks and replacement pods. Future growth will depend partly on reliable production quality, rapid field communication and data systems that distinguish defective lots from unaffected supplies.
Device automation separates sensor-integrated automated delivery from manually programmed electronic basal-bolus pumps and non-electronic mechanical insulin patches. Classification follows the delivered product's control mechanism, not whether the user owns a CGM.
Automated patch pumps represented an estimated ~76% of 2025 revenue, led by Omnipod 5. The system can modify basal insulin delivery using compatible glucose-sensor readings and has U.S. indications for type 1 diabetes and adults with type 2 diabetes. Insulet reported USD 2.674 billion of Omnipod product sales across its portfolio in 2025. The modeled automated share is not a company-disclosed breakdown of Omnipod 5 revenue.
Manually programmed devices deliver basal and bolus insulin using user-selected settings without requiring a closed-loop algorithm. Medtrum TouchCare Nano can be controlled through a handset or smartphone, while Roche Accu-Chek Solo offers a detachable modular micropump and direct bolus buttons. These products address people who value tubeless wear but use different glucose-monitoring or dosing routines. Sales of Medtrum and Roche devices depend on approved country availability and purchases of their particular replacement components.
Mechanical patches use preset or button-actuated delivery without automated glucose-sensor feedback. MannKind V-Go provides daily basal-bolus insulin through a wearable mechanical device, whereas CeQur Simplicity delivers mealtime boluses only. Their simpler electronics profile can lower user interaction requirements, but clinical indications and dosing flexibility differ from Omnipod 5. This category is modeled separately so a bolus-only patch is not described as an automated insulin pump.
Automated patch systems should capture most incremental value through 2034 as algorithms and sensor compatibility improve. Mechanical products retain a niche among users seeking injection reduction without full pump automation.
Patient indication is assigned to the diagnosed diabetes type for which the device is prescribed. Type 1 and insulin-treated type 2 categories are mutually exclusive at the user level, even when a device has labels for both.
Type 1 diabetes represented an estimated ~79% of 2025 revenue because intensive insulin therapy has historically driven patch-pump adoption. Insulet launched Omnipod 5 across European markets for patients aged two and older with type 1 diabetes. Automated delivery can reduce some manual basal adjustments, but meal boluses and safety monitoring remain important. The patient allocation is modeled and should not be mistaken for a disclosed revenue split by diagnosis.
The August 2024 U.S. clearance extended Omnipod 5 to adults with type 2 diabetes, opening a larger treatment population. MannKind V-Go also serves adults who require insulin with a preset basal-bolus mechanical patch. The opportunity depends on payer coverage, training and whether a patient benefits from automated or simpler dosing. Type 2 growth is expected to exceed the overall market rate from a smaller starting base.
A clinician must consider daily insulin dose, skin tolerance, manual dexterity, ability to respond to alarms and access to compatible CGM devices. Medtrum offers 200- and 300-unit Nano reservoirs, while Roche Solo uses a 200-unit detachable micropump. Mechanical patches may have fixed basal rates or bolus-only functionality. Selection therefore depends on therapeutic requirements rather than a generic preference for wearable electronics.
Type 1 diabetes remains the value leader, while the type 2 share should increase as indications, reimbursement and clinician experience broaden. Non-insulin-treated type 2 diabetes is outside the defined addressable market.
Purchasing channel identifies where the patch-pump device is purchased or dispensed, not where the patient receives diabetes education. Retail pharmacy, clinic and durable medical equipment channels are separate revenue allocations.
Retail pharmacy and home fulfillment represented an estimated ~66% of 2025 revenue. Insulet describes Omnipod as a pharmacy-accessible tubeless system and reported more than 600,000 active customers globally at year-end. Recurring disposable pod prescriptions favor refill-based distribution and home delivery. Pharmacy channel revenue includes the device and its consumables, excluding the insulin filled into each pod and independently purchased CGM sensors.
Diabetes clinics often initiate therapy, train users on cannula placement and review automated delivery settings. Roche Solo and Medtrum Nano systems may be supplied through clinic-linked channels depending on local reimbursement. Hospitals also manage complications and device troubleshooting, but clinical consultation fees are not part of patch-pump hardware revenue. This category counts devices billed through clinics rather than all patients referred by a specialist.
Specialty DME providers may distribute pumps and replacement components under medical equipment benefits in some countries. Device coverage rules, replacement intervals and documentation requirements differ from pharmacy claims. Manufacturers and payers can shift products between routes over time, so this category reflects the invoiced dispensing channel rather than a permanent characteristic of a brand. It does not include conventional tubed pumps supplied through the same distributors.
Home-based pod replenishment should remain commercially important as the installed user base grows. Provider training and payer authorization can influence uptake even when the device itself is ultimately dispensed through a pharmacy.
Replacement design describes the physical product architecture: fully disposable multi-day pods, detachable reusable micropumps or daily mechanical patches. A device is assigned once according to the main insulin-delivery component sold.
Disposable multi-day pods represented an estimated ~88% of 2025 revenue because Omnipod products account for most disclosed category sales. A typical Omnipod pod provides up to three days of insulin delivery before replacement, creating recurring consumption as users remain on therapy. Medtrum Nano also offers up to three days of tubeless wear. Revenue covers the pod hardware and associated system components, not insulin medication.
Roche Accu-Chek Solo has a detachable micropump with separately replaceable components, allowing a user to remove and reattach the pump without discarding insulin. The modular approach changes the frequency and price of component purchases relative to a fully disposable pod. It is commercially available in selected European markets, so the forecast avoids assuming universal geographic access. Device maintenance and replacement parts remain within scope when sold with the insulin delivery system.
MannKind V-Go is worn for twenty-four hours and delivers a preset basal rate plus on-demand boluses. CeQur Simplicity provides mealtime boluses and can be worn for up to four days, so it is grouped here with short-cycle mechanical patch designs rather than reusable electronic pumps. The category has lower technical complexity but different clinical functions, and no automated insulin adjustment should be implied.
Disposable pod revenue grows with the active user population and refill adherence. Modular and mechanical alternatives can attract users with different cost, dosing or convenience requirements, but they are not interchangeable treatment devices.
Regional adoption depends on insulin pump reimbursement, diabetes specialist capacity, pharmacy access and device approvals. North America leads modeled value, with Europe supplying several competing patch formats and Asia-Pacific expanding access to tubeless pumps.
North America accounted for an estimated ~62% of 2025 wearable insulin patch pump revenue, reflecting Insulet's USD 1.9198 billion U.S. Omnipod sales and its established pharmacy distribution. The August 2024 FDA clearance for adults with type 2 diabetes widened the eligible population, and Insulet reported more than 600,000 global active users at the end of 2025. In 2026, the company recorded 24.6% second-quarter Omnipod revenue growth, though it also issued two separate device corrections. The FDA's May action identified potential insulin under-delivery in certain lots, reinforcing the importance of manufacturing quality and replacement procedures. Canada became an additional Omnipod 5 launch market in 2025, supporting regional growth beyond the United States. MannKind V-Go and CeQur Simplicity provide mechanical insulin patch alternatives for selected adult treatment needs.
Insulet reported USD 1.9198 billion in U.S. Omnipod revenue during 2025 and gained an adult type 2 indication for Omnipod 5 in August 2024. The FDA posted corrections in March and May 2026 for selected pod lots with possible insulin leakage. Providers must distinguish unaffected devices from recalled lots and train users to respond promptly to unexpected hyperglycemia.
Source: Insulet.
Insulet announced in March 2025 that Omnipod 5 would launch in Canada later that spring, alongside expansions to Australia, Belgium and Switzerland. Canadian uptake depends on provincial reimbursement, diabetes education and compatible sensor availability. Device sales enter the regional model when actually supplied, not simply because a launch was announced for a future date.
Source: Insulet.
Europe is a major market for tubeless insulin delivery because Insulet, Roche and Medtrum have product availability across selected countries. Omnipod 5 launched in Italy, Denmark, Finland, Norway and Sweden in January 2025, following broader access in the United Kingdom and Netherlands during 2024. Roche markets the Accu-Chek Solo detachable micropump, with its CE mark announced in 2018, while Medtrum sells TouchCare Nano patch pumps in European markets. Insulet also introduced Omnipod 5 in Spain during 2026, expanding its regional footprint. Reimbursement and prescribing pathways vary by country, affecting adoption even when a device has regulatory clearance. The region is also exposed to manufacturing correction notices for affected Omnipod lots distributed internationally. Device revenue is counted separately from continuous glucose monitoring sensors and clinical service charges.
Insulet completed the full commercial launch of Omnipod 5 in the United Kingdom in June 2024 with Dexcom G6 and Abbott FreeStyle Libre 2 Plus integration. British clinical use requires patient education on automated mode, glucose sensor pairing and locally applicable funding arrangements. The tubeless design can reduce infusion-set handling, while CGM sensors remain separate products that are not included in patch-pump hardware revenue.
Source: Insulet.
Insulet reported an Omnipod 5 launch in Spain during its August 2026 second-quarter update, calling it the twenty-sixth country with Omnipod sales. Roche also lists the Accu-Chek Solo tube-free micropump on its Spanish product site. These devices have different control and replacement architectures, and the local market depends on reimbursement and clinician training rather than a single pan-European pump purchasing model.
Source: Insulet.
Asia-Pacific demand is supported by diabetes prevalence, pump therapy awareness and country-specific access to wearable delivery devices. Insulet introduced Omnipod 5 in Australia during March 2025, with compatibility for Dexcom G6 and G7 sensors at launch. Medtrum offers a compact TouchCare Nano tubeless patch pump and markets different configurations depending on the country, including 200- and 300-unit reservoirs. Japan, China and other markets require local regulatory and reimbursement evaluation before any imported system can be widely used. Regional competition is therefore influenced by affordability, distributor support and the availability of trained diabetes clinicians. The model does not equate the large number of people with diabetes in Asia with immediate patch-pump demand; only insulin-treated patients with access to the device are addressable.
Insulet announced that Omnipod 5 was commercially available in Australia in March 2025 with Dexcom G6 and G7 compatibility, with plans to add another Abbott sensor. The launch expanded access to tubeless automated insulin delivery for eligible patients. Local reimbursement and specialist training determine sustained adoption after the initial product introduction.
Source: Insulet.
Medtrum develops the TouchCare Nano patch pump with 200- and 300-unit reservoir options and optional CGM integration. The manufacturer states that marketed models differ by country, so a Chinese product listing should not be assumed to apply to all international markets. Procurement depends on local device approvals, training and affordability rather than the broader sales of glucose monitoring sensors.
Source: Medtrum.
Latin America accounts for a smaller part of wearable insulin patch pump revenue in the regional estimate because device affordability and reimbursement vary substantially across countries. Roche provides an Accu-Chek Solo product information portal for Latin America, demonstrating availability of technical materials for a tube-free micropump. However, a regional website does not prove commercial supply in every national market, so revenue is allocated conservatively. Insulet's international expansion has prioritized Europe, Australia and selected Middle Eastern markets during the documented 2025–2026 period. In Brazil and Mexico, access to specialist diabetes services, recurring consumable coverage and reliable replacement pod distribution are practical constraints. Mechanical patches may appeal to some insulin-treated adults, but their country-specific registration and reimbursement must be verified before assigning local sales.
Roche's Latin American portal describes the Accu-Chek Solo detachable tubeless micropump and its technical specifications, but country-specific availability must be checked. Brazil's diabetes clinics may evaluate patch pumps for patients needing intensive insulin therapy, subject to device authorization and funding. The forecast does not count conventional tubed pump sales or separately dispensed insulin medication as wearable patch-pump revenue.
Source: Roche Diabetes Care.
Patch pump adoption in Mexico depends on product registration, insurance and specialist training. International manufacturer information establishes that tubeless systems exist, but does not verify a specific Mexican launch date for every brand. The regional estimate therefore treats Mexico as a potential growth market rather than assuming immediate broad pharmacy access to Omnipod 5, Medtrum Nano or Roche Solo.
Source: Roche Diabetes Care.
Middle East and African markets are smaller in the global value model, but Insulet expanded its regional presence during 2026. The company launched Omnipod 5 and its Discover data platform in Saudi Arabia, Kuwait, the United Arab Emirates and Qatar, with local sensor compatibility varying by market. These launches create a pathway for recurring disposable pod sales once reimbursement and clinician training are established. In African countries, access to automated insulin delivery remains uneven because pump hardware, CGM sensors and ongoing supplies can be expensive. Manufacturers must also maintain distribution and replacement processes for safety notices affecting particular lots. The forecast therefore assumes gradual regional uptake rather than applying North American per-patient device spending to all insulin-treated people with diabetes.
Insulet announced Omnipod 5 availability in Saudi Arabia during 2026, alongside Omnipod Discover data management. The company identified compatibility with Abbott FreeStyle Libre 2 Plus and Dexcom G7 in the market. Device adoption will depend on reimbursement, clinician training and ongoing pod supply, while separately purchased glucose sensors remain outside the patch-pump revenue calculation.
Source: Insulet.
Omnipod 5 launched in the UAE as part of Insulet's 2026 Middle Eastern rollout, with compatible sensor options identified by the company. Patients need appropriate insulin dosing education and access to replacement pods. Local device sales are counted when supplied to users; regional diabetes prevalence alone is not a revenue proxy for automated patch pumps.
Source: Insulet.
The wearable insulin patch market is highly concentrated in Insulet's Omnipod platform, but several other manufacturers offer distinct electronic or mechanical delivery formats. Commercial comparisons must separate automated systems, manual micropumps and bolus-only patches.
Insulet disclosed USD 2.674 billion of 2025 Omnipod product revenue and more than 600,000 estimated active users. Omnipod 5 has automated delivery and type 1 and type 2 indications in the United States. The company expanded internationally but faced two manufacturing corrections in 2026.
Medtrum TouchCare Nano offers a 200-unit tubeless pump and a 300-unit variant with smartphone or handset control and optional CGM integration. The Medtrum product page states that pump configurations offered for sale differ among national markets. The compact design addresses patients seeking multi-day wear without external tubing.
Roche Accu-Chek Solo is a detachable, tube-free micropump with a 200-unit reservoir and direct bolus buttons. It received a European CE mark in 2018 and is listed on Roche product portals in selected countries. Its reusable architecture differs from a fully disposable Omnipod pod.
MannKind V-Go provides a daily mechanical basal-bolus patch, while CeQur Simplicity is a bolus-only mealtime insulin patch. Both are described in the American Diabetes Association consumer guide. Neither product should be presented as an automated CGM-integrated insulin pump.
Insulet benefits from recurring disposable pod purchases and broadening international distribution. Its 2025 Omnipod revenue grew 31.6% from 2024, and the company initially projected 21–23% constant-currency growth for 2026 before revising guidance in August. The model uses a lower long-term 16% annual growth assumption because early adoption rates are unlikely to persist unchanged across nine years. Other-supplier revenue is represented by a 12% allowance, not invented individual company sales figures.
Competitive differentiation includes reservoir capacity, wear duration, pump removability, sensor compatibility and patient training burden. Medtrum Nano offers 200- and 300-unit configurations, Roche Solo has a detachable design, and Omnipod 5 uses an automated algorithm. MannKind V-Go and CeQur Simplicity reduce injection frequency without replicating all electronic pump functions. This variety means unit-price comparisons require matching therapeutic indications and replacement cycles rather than treating every adhesive insulin device as interchangeable.
The 2026 Omnipod corrections highlight the importance of manufacturing traceability and timely patient communication. The FDA advised users to check affected lots and replace specified pods, while unaffected products remained in use. Safety performance, reimbursement negotiations and compatible CGM availability will shape future competition alongside algorithm development. Providers that combine robust field support with dependable pod supply may retain users even when rival products offer lower upfront device costs.
August 2026: Insulet reported USD 795.9 million of second-quarter Omnipod revenue, up 24.6%, and launched Omnipod 5 in Spain. The company also described expanded FreeStyle Libre 3 Plus compatibility and a next-generation dosing algorithm. The developments show continued international and technology investment, while its updated guidance signaled a more measured growth trajectory. Source
May 2026: The FDA posted a separate Omnipod pod medical device correction involving selected Omnipod 5, DASH and Eros lots. Insulet identified potential insulin leakage and under-delivery, with roughly seven million pods within the action and twenty-four serious adverse events reported at announcement. The notice reinforced the need for lot checks and prompt replacement of affected devices. Source
March 2026: Insulet initiated an earlier Omnipod 5 correction for specific U.S. lots after identifying potential internal tubing tears. The FDA notice described risks of elevated blood glucose and diabetic ketoacidosis if insulin delivery was interrupted. Unaffected pods continued to be sold, and the company implemented manufacturing control changes. Source
February 2026: Insulet reported USD 2.674 billion in full-year 2025 Omnipod product revenue, 31.6% above the previous year, and more than 600,000 estimated active users. Its February outlook projected 21–23% Omnipod growth in constant currency for 2026, providing a direct company sales baseline for this market's modeled revenue estimate. Source
March 2025: Insulet announced Omnipod 5 availability in Australia and upcoming launches in Belgium, Canada and Switzerland. The expansion added compatible Dexcom sensor options in several markets. International product access broadens recurring pod demand, although individual country reimbursement and training arrangements determine uptake after launch. Long-term refill adherence requires affordable pod replacement and continuing diabetes-clinic support. Source
January 2025: Insulet launched Omnipod 5 in Italy, Denmark, Finland, Norway and Sweden, with Abbott FreeStyle Libre 2 Plus and Dexcom G6 compatibility. The five-country rollout extended tubeless automated insulin delivery to additional European patients with type 1 diabetes. The glucose sensors themselves remain outside the patch-pump device revenue model. Source
August 2024: The FDA-cleared Omnipod 5 type 2 diabetes indication extended automated insulin delivery to U.S. adults aged eighteen and older with type 2 diabetes. The label expansion opened a new clinical segment beyond its established type 1 population, while continuing to require appropriate insulin management and compatible glucose sensing. Source
Modeled wearable insulin patch pump revenue expands from USD 3.474 billion in 2026 to USD 11.389 billion in 2034, corresponding to 16.0% annual compound growth. The estimate is based on disclosed 2025 Omnipod product sales, not a publisher-provided market-size series.
| Forecast Variable | Observed Evidence | Implication for 2034 |
|---|---|---|
| Installed user base | More than 600,000 Omnipod users in 2025 | Recurring pod replenishment supports device revenue |
| Type 2 indication | U.S. clearance in August 2024 | Larger insulin-treated eligible population |
| International expansion | Nine Omnipod market launches in 2025 | Broader country-level pharmacy distribution |
| Product quality | FDA corrections in March and May 2026 | Higher monitoring and replacement costs |
| Competitive formats | Medtrum, Roche, MannKind and CeQur | Different price points and therapy requirements |
North America should remain the largest revenue region because U.S. Omnipod sales already accounted for USD 1.9198 billion in 2025. Europe provides broader competition through Roche Solo and Medtrum Nano, while Insulet continues expanding its automated platform. Asia-Pacific offers incremental demand through Australia and other eligible markets, but adoption requires device approval, training and reimbursement. The 2026 Middle Eastern rollout demonstrates another avenue for growth from a smaller base.
Automated insulin delivery patches are expected to grow faster than mechanical devices because glucose-sensor integration can reduce manual basal adjustments. The type 2 diabetes indication expands the potential population, although not every insulin-treated adult will benefit from a closed-loop system. Disposable pods create recurring revenue after initial adoption, while modular micropumps and mechanical patches follow different replacement cycles. Forecast values exclude the glucose sensors and insulin medicines needed for therapy.
Risks include manufacturing quality, reimbursement changes, device cost and compatibility with the user's existing glucose monitor. The FDA posted two distinct Omnipod correction actions during 2026, demonstrating that a product can remain commercially available while specific lots must be replaced. Insulet also revised its 2026 guidance after assessing type 2 rollout dynamics. These factors support a more conservative 16% long-term growth assumption than the company's 31.6% Omnipod growth recorded in 2025.
Competitive opportunity lies in improving comfort, simplifying training and supporting patients across type 1 and insulin-treated type 2 diabetes. Medtrum offers higher-capacity tubeless reservoirs, Roche uses a detachable modular format, and mechanical patches serve users who do not need automated basal control. Reliable replacement supply and post-market safety communication will remain important. The 12% other-supplier allowance is explicitly modeled and should not be presented as audited worldwide sales for competing brands.
Coverage includes marketed wearable insulin delivery hardware and directly related consumables, with four independent segmentation axes and five geographic regions.
The modeled 2025 market is USD 2.995 billion. Insulet disclosed USD 2.674 billion in 2025 Omnipod sales; a separate 12% allowance estimates the contribution of other qualified patch suppliers. Worldwide revenue beyond Insulet is not independently audited.
The 2034 model reaches USD 11.389 billion from USD 3.474 billion in 2026, equal to a 16.0% CAGR. Growth is assumed to be slower than Insulet's 31.6% Omnipod sales increase in 2025, reflecting a longer forecast horizon and potential reimbursement constraints.
A patch pump attaches directly to the skin and delivers insulin without long external tubing. Conventional tubed insulin pumps deliver through a separate infusion set connected by external tubing. Omnipod 5 and Medtrum Nano are tubeless electronic systems, while Roche Solo is detachable and MannKind V-Go is a mechanical patch.
Insulet is the clear leader in disclosed sales, reporting USD 2.674 billion of Omnipod product revenue in 2025. The company estimated more than 600,000 active users globally at year-end. Other suppliers generally do not publish comparable patch-pump-only revenue figures.
Yes, specific patch-pump devices are authorized for insulin-treated type 2 diabetes in certain markets. The FDA cleared Omnipod 5 for U.S. adults with type 2 diabetes in August 2024, and MannKind V-Go is designed for adults requiring insulin. Suitability depends on insulin needs, training and local product labeling.
No. Omnipod 5 is an electronic automated insulin delivery system that can use compatible glucose-sensor readings. CeQur Simplicity is a mechanical mealtime bolus patch and does not provide automated basal insulin. Omnipod 5 supports automated basal adjustment, whereas CeQur Simplicity delivers only manually requested mealtime boluses over its multi-day wear cycle.
The FDA posted separate corrections in March and May 2026 for selected Omnipod lots with possible insulin leakage and under-delivery. The broader May action included roughly seven million pods, with twenty-four serious adverse events reported at announcement. The FDA advised continued use of unaffected Omnipod lots while instructing users to identify and replace specified devices.
North America leads the modeled regional split at 62% of 2025 revenue, supported by USD 1.9198 billion in U.S. Omnipod sales. Europe and Asia-Pacific are expanding through new product launches and additional device formats. The 62% regional figure is a market-model allocation informed by Insulet's disclosed U.S. revenue.
Medtrum TouchCare Nano offers a tubeless electronic pump, and Roche Accu-Chek Solo provides a detachable micropump. MannKind V-Go and CeQur Simplicity are mechanical insulin patches with different dosing functions. Product availability and approved clinical indications differ across national regulatory markets, including Europe and the United States.
No. The forecast covers wearable insulin delivery hardware, pods, controllers and device-specific consumables. Separately sold glucose sensors, insulin vials, clinical appointments and conventional tubed pumps are excluded to avoid counting unrelated diabetes revenues twice. This boundary prevents inflation of device revenue by diabetes drug sales.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.